BTK and COVID-19: In another CLL cohort, where 79% of the patients had been hospitalized for COVID-19, CLL disease burden significantly impacted on outcome: milder disease was observed in untreated patients, age did not impact on mortality and BTK inhibitors appeared to exert a protective effect, as observed in the CLL patients we studied [23].